TL;DR
This paper reveals that the minor spliceosome (MiS), a less-studied component of the cellular splicing machinery, plays a critical role in prostate cancer (PCa) progression, particularly in therapy resistance and the development of lethal forms of the disease. Inhibiting MiS, specifically through targeting U6atac snRNA, effectively blocks cancer cell proliferation and shows promise as a therapeutic strategy.
What Problem Does This Paper Address?
Prostate cancer (PCa) is a complex disease with a significant challenge in treating advanced, castration-resistant forms (CRPC) and the aggressive neuroendocrine subtype (CRPC-NE). While the major spliceosome is well-understood, the role of the minor spliceosome (MiS) in cancer, especially in the context of therapy resistance and lineage plasticity (adenocarcinoma to neuroendocrine), has been largely unexplored. This paper aims to elucidate the function of MiS in PCa progression and investigate its potential as a therapeutic target.
Methods
The study employed a multi-pronged approach combining:
- RNA sequencing (RNAseq) and single-cell RNA sequencing (scRNAseq) to analyze gene expression and identify changes in minor intron retention and alternative splicing.
- Mass spectrometry (LC-MS/MS) to assess differential protein production.
- Flow cytometry (FACS) to analyze cell cycle progression.
- Luciferase reporter assays and minigene reporter assays to directly measure minor and major intron splicing efficiency.
- Co-immunoprecipitation (Co-IP) and Proximity Ligation Assay (PLA) to investigate protein-protein interactions.
- In-situ hybridization (ISH) to visualize U6atac expression in tissues.
- Cell viability and growth curve assays to assess the impact of MiS inhibition on cancer cells.
- Bioinformatic analyses including protein-protein interaction network analysis, principal component analysis (PCA), hierarchical sample clustering, Silhouette coefficient analysis, DAVID analysis, STRING, Ingenuity Pathway Analysis (IPA), and Gene Set Enrichment Analysis (GSEA).
Datasets
The study utilized several publicly available datasets:
- GTEx: Normal prostate tissue samples.
- TCGA: Primary prostate cancer samples.
- SU2C: Advanced prostate cancer samples (CRPC-adeno and CRPC-NE).
- PCAWG: Gene expression data from nine distinct cancer types.
- HINT database: Human protein-protein interaction network.
- Cancer Genome Interpreter database: List of cancer-causing genes.
Raw RNAseq and scRNAseq data were submitted to the European Genome-phenome Archive (EGAS00001005546). Mass spectrometry proteomics data were deposited to the ProteomXchange Consortium (PXD026949).
Key Insights and Ideas
- MiS is upregulated in aggressive PCa: Minor intron splicing efficiency and the expression of MiS components (like U6atac snRNA) significantly increase as PCa progresses to castration-resistant and neuroendocrine forms. This suggests MiS activity is actively regulated and enhanced during disease progression.
- AR signaling drives MiS activity: Androgen Receptor (AR) signaling, a key driver in PCa, directly influences MiS activity. This connection is crucial for understanding therapy resistance mechanisms.
- MiS inhibition causes cell cycle arrest: Targeting MiS components leads to aberrant minor intron splicing, resulting in severe cell cycle defects (G1/S arrest) and impacting critical pathways like MAPK signaling and DNA repair.
- MiS is a potential pan-cancer target: The findings suggest that MiS inhibition is not only effective against PCa but may also be detrimental to other cancer types, highlighting its broad therapeutic potential.
Key Results
- Increased expression of MiS U6atac snRNA and 6x more efficient minor intron splicing were observed in CRPC compared to primary PCa.
- Inhibition of MiS via siU6atac led to aberrant minor intron splicing, affecting numerous minor intron-containing genes (MIGs) and impacting MAPK activity, DNA repair, and cell cycle pathways.
- Single-cell RNAseq confirmed cell cycle defects and lineage dependency on MiS from primary to CRPC and neuroendocrine PCa.
- siU6atac treatment was approximately 50% more efficient in reducing tumor burden of CRPC cells and organoids compared to current state-of-the-art combination therapies.
- MiS inhibition significantly reduced AR activity and EMT scores in PCa cells and organoids.
- Targeting MiS components (U6atac, RNPC3) significantly decreased proliferation and viability in various PCa cell lines and organoids, while sparing non-cancer cells.
- MiS inhibition showed synergistic effects with cisplatin in bladder cancer cells and was more effective than EZH2 inhibition plus enzalutamide in CRPC cells.
Limitations and Future Work
- Cell type-specific effects: The study acknowledges that MiS inhibition can have differential effects based on the cell type and the specific MiS component targeted. Future work could explore these nuances further.
- Combination therapies: While siU6atac showed promise alone and in combination with cisplatin and enzalutamide, further research is needed to optimize combination strategies for various cancer types.
- Diagnostic marker potential: The correlation of U6atac expression with PCa progression suggests its potential as a diagnostic marker, which warrants further validation.
- Broader cancer applicability: The study hints at MiS being essential for other cancer types, suggesting future research could investigate its role and therapeutic potential in a wider range of malignancies.
Summary updated